ID
SRPT icon

Integral Derivatives’s Sarepta Therapeutics SRPT Stock Holding History

Integral Derivatives’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		$252K Sell
3,400
-6,300
-65% -$420K 0.01% 556
2017
Q4 		$540K Sell
9,700
-8,100
-46% -$429K 0.01% 689
2017
Q3 		$807K Sell
17,800
-23,500
-57% -$939K 0.01% 570
2017
Q2 		$1.39M Buy
41,300
+30,400
+279% +$990K 0.03% 390
2017
Q1 		$323K Sell
10,900
-10,300
-49% -$319K 0.01% 881
2016
Q4 		$582K Sell
21,200
-12,200
-37% -$490K 0.01% 677
2016
Q3 		$2.05M Sell
33,400
-11,200
-25% -$339K 0.04% 261
2016
Q2 		$851K Buy
+44,600
New +$826K 0.02% 458
2016
Q1 		– Sell
-5,800
Closed -$224K – 1083
2015
Q4 		$224K Sell
5,800
-1,400
-19% -$45.4K 0.01% 903
2015
Q3 		$231K Buy
+7,200
New +$244K 0.01% 934
2014
Q2 		– Sell
-20,600
Closed -$495K – 1500
2014
Q1 		$495K Sell
20,600
-21,200
-51% -$541K 0.01% 889
2013
Q4 		$851K Buy
+41,800
New +$1.24M 0.01% 847

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Integral Derivatives's SRPT Position: Q1 2014 in Review

Integral Derivatives sold out of Sarepta Therapeutics (SRPT) in Q1 2014, closing a stake of 14,622 shares — an estimated $373K sold.

Integral Derivatives first reported a position in SRPT in Q4 2013 and held it in 1 quarter. The position peaked at $298K in Q4 2013. 114 funds tracked by Wall St. Rank hold SRPT as of Q1 2014.

  • Integral Derivatives reported no remaining Sarepta Therapeutics position as of Q1 2014 after selling out during the quarter.
  • Integral Derivatives sold 14,622 Sarepta Therapeutics shares in Q1 2014, an estimated $373K.
  • Integral Derivatives first reported a position in Sarepta Therapeutics in Q4 2013 and held it in 1 quarter.
  • Integral Derivatives's Sarepta Therapeutics position peaked at $298K in Q4 2013.
  • 114 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2014.

Based on Integral Derivatives's 13F filing for Q1 2014, filed 2 May 2014.